Modern approaches to cardiovascular amyloidosis treatment

Cardiovascular (cardiac) amyloidosis (CA) is a clinical pathology, usually of a geneticallymediated nature, initiated by the precipitation process of the insoluble fibrous protein with β-pleated sheet secondary structure. Such anomalous changes lead to the formation of amyloid fibrils, which may giv...

Full description

Saved in:
Bibliographic Details
Main Authors: Svetlana N. Morozkina, Petr P. Snetkov, Roman O. Olekhnovich, Mayya V. Uspenskaya
Format: Article
Language:English
Published: Limited liability company «Science and Innovations» (Saratov) 2021-12-01
Series:Russian Open Medical Journal
Subjects:
Online Access:https://romj.org/node/417
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850132228676255744
author Svetlana N. Morozkina
Petr P. Snetkov
Roman O. Olekhnovich
Mayya V. Uspenskaya
author_facet Svetlana N. Morozkina
Petr P. Snetkov
Roman O. Olekhnovich
Mayya V. Uspenskaya
author_sort Svetlana N. Morozkina
collection DOAJ
description Cardiovascular (cardiac) amyloidosis (CA) is a clinical pathology, usually of a geneticallymediated nature, initiated by the precipitation process of the insoluble fibrous protein with β-pleated sheet secondary structure. Such anomalous changes lead to the formation of amyloid fibrils, which may give rise to various forms of amyloidosis. Amyloid formation can be found in various organs and systems, such as cardiovascular system, central and peripheral nervous systems, liver, urinary tract, etc. CA is a rare degenerative disease resulting in congestive cardiac failure and heart arrhythmia with subsequent untimely death. Unfortunately, up to date, the choice of medications for treating amyloidosis is very limited. In this paper, we review clinically used pharmaceutical drugs for CA treatment, along with some delivery systems for such compounds.
format Article
id doaj-art-ecf1898c782a499cb75a464a6e37f062
institution OA Journals
issn 2304-3415
language English
publishDate 2021-12-01
publisher Limited liability company «Science and Innovations» (Saratov)
record_format Article
series Russian Open Medical Journal
spelling doaj-art-ecf1898c782a499cb75a464a6e37f0622025-08-20T02:32:15ZengLimited liability company «Science and Innovations» (Saratov)Russian Open Medical Journal2304-34152021-12-01104e041610.15275/rusomj.2021.0416Modern approaches to cardiovascular amyloidosis treatmentSvetlana N. MorozkinaPetr P. SnetkovRoman O. OlekhnovichMayya V. UspenskayaCardiovascular (cardiac) amyloidosis (CA) is a clinical pathology, usually of a geneticallymediated nature, initiated by the precipitation process of the insoluble fibrous protein with β-pleated sheet secondary structure. Such anomalous changes lead to the formation of amyloid fibrils, which may give rise to various forms of amyloidosis. Amyloid formation can be found in various organs and systems, such as cardiovascular system, central and peripheral nervous systems, liver, urinary tract, etc. CA is a rare degenerative disease resulting in congestive cardiac failure and heart arrhythmia with subsequent untimely death. Unfortunately, up to date, the choice of medications for treating amyloidosis is very limited. In this paper, we review clinically used pharmaceutical drugs for CA treatment, along with some delivery systems for such compounds.https://romj.org/node/417drug delivery systemcardiovascular amyloidosistransthyretintafamidisdiflunisal
spellingShingle Svetlana N. Morozkina
Petr P. Snetkov
Roman O. Olekhnovich
Mayya V. Uspenskaya
Modern approaches to cardiovascular amyloidosis treatment
Russian Open Medical Journal
drug delivery system
cardiovascular amyloidosis
transthyretin
tafamidis
diflunisal
title Modern approaches to cardiovascular amyloidosis treatment
title_full Modern approaches to cardiovascular amyloidosis treatment
title_fullStr Modern approaches to cardiovascular amyloidosis treatment
title_full_unstemmed Modern approaches to cardiovascular amyloidosis treatment
title_short Modern approaches to cardiovascular amyloidosis treatment
title_sort modern approaches to cardiovascular amyloidosis treatment
topic drug delivery system
cardiovascular amyloidosis
transthyretin
tafamidis
diflunisal
url https://romj.org/node/417
work_keys_str_mv AT svetlananmorozkina modernapproachestocardiovascularamyloidosistreatment
AT petrpsnetkov modernapproachestocardiovascularamyloidosistreatment
AT romanoolekhnovich modernapproachestocardiovascularamyloidosistreatment
AT mayyavuspenskaya modernapproachestocardiovascularamyloidosistreatment